BRPI0717976A2 - Composto ou um sal farmaceuticamente aceitável do mesmo, composição, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo - Google Patents

Composto ou um sal farmaceuticamente aceitável do mesmo, composição, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo Download PDF

Info

Publication number
BRPI0717976A2
BRPI0717976A2 BRPI0717976-6A BRPI0717976A BRPI0717976A2 BR PI0717976 A2 BRPI0717976 A2 BR PI0717976A2 BR PI0717976 A BRPI0717976 A BR PI0717976A BR PI0717976 A2 BRPI0717976 A2 BR PI0717976A2
Authority
BR
Brazil
Prior art keywords
alkyl
substituted
group
unsubstituted
phenyl
Prior art date
Application number
BRPI0717976-6A
Other languages
English (en)
Portuguese (pt)
Inventor
David Chen
Christopher L Franklin
Peter R Guzzo
Lins S Lin
Michael M-C Lo
Ravi P Nargund
Iyassu K Sebhat
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0717976A2 publication Critical patent/BRPI0717976A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0717976-6A 2006-10-20 2007-10-16 Composto ou um sal farmaceuticamente aceitável do mesmo, composição, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo BRPI0717976A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85319306P 2006-10-20 2006-10-20
US60/853193 2006-10-20
PCT/US2007/022087 WO2008051406A2 (en) 2006-10-20 2007-10-16 Substituted imidazoles as bombesin receptor subtype-3 modulators

Publications (1)

Publication Number Publication Date
BRPI0717976A2 true BRPI0717976A2 (pt) 2013-11-12

Family

ID=39325111

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717976-6A BRPI0717976A2 (pt) 2006-10-20 2007-10-16 Composto ou um sal farmaceuticamente aceitável do mesmo, composição, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo

Country Status (13)

Country Link
US (1) US8193228B2 (enExample)
EP (1) EP2091937A2 (enExample)
JP (1) JP5047299B2 (enExample)
KR (1) KR20090064458A (enExample)
CN (1) CN101528730A (enExample)
AU (1) AU2007309570B2 (enExample)
BR (1) BRPI0717976A2 (enExample)
CA (1) CA2666310C (enExample)
IL (1) IL198004A0 (enExample)
MX (1) MX2009004112A (enExample)
NO (1) NO20091957L (enExample)
RU (1) RU2009118935A (enExample)
WO (1) WO2008051406A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083822A2 (en) 2006-10-20 2009-08-05 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
WO2009123164A1 (ja) * 2008-04-02 2009-10-08 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013135674A1 (en) * 2012-03-12 2013-09-19 Syngenta Participations Ag Insecticidal 2-aryl-acetamide compounds
CN103497159B (zh) * 2013-09-18 2015-08-12 苏州岚云医药科技有限公司 1,2-二取代-5-磺酰基咪唑类化合物的制备方法
LT3364958T (lt) 2015-10-23 2023-06-12 Navitor Pharmaceuticals, Inc. Sestrin-gator2 sąveikos moduliatoriai ir jų panaudojimas
CN116370448B (zh) 2017-04-26 2026-01-13 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂及其用途
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
TWI870497B (zh) 2019-11-01 2025-01-21 美商奈維特製藥公司 使用mtorc1調節劑的治療方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962117A (en) 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
JPH07243068A (ja) 1994-03-08 1995-09-19 Murata:Kk 金属表面の電解処理方法
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EA003056B1 (ru) 1996-12-23 2002-12-26 Дюпон Фармасьютикалз Компани АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
JPH11217348A (ja) 1997-10-15 1999-08-10 Otsuka Pharmaceut Co Ltd フルオレノン誘導体の製造法
IL136637A0 (en) 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
JP3842976B2 (ja) 2000-03-17 2006-11-08 富士通株式会社 分布帰還型半導体レーザとその製造方法
ATE542805T1 (de) 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
US7687664B2 (en) 2001-06-04 2010-03-30 Eisai R&D Management Co., Ltd. Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
KR100901683B1 (ko) 2001-08-10 2009-06-08 닛뽕 케미파 가부시키가이샤 퍼옥시좀 증식제 응답성 수용체 δ의 활성화제
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2003321455A (ja) 2002-02-28 2003-11-11 Nissan Chem Ind Ltd ｏ−置換ベンゾイル化合物及びこれを有効成分とする除草剤
DE10224844A1 (de) 2002-06-05 2004-01-08 Solvay Pharmaceuticals Gmbh Nicht-peptidische BRS-3-Agonisten
WO2004007464A1 (ja) 2002-07-10 2004-01-22 Sumitomo Pharmaceuticals Co., Ltd. イミダゾール誘導体
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
BR0314898A (pt) 2002-11-19 2005-08-02 Galderma Res & Dev Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
WO2004048351A2 (en) 2002-11-25 2004-06-10 Galderma Research & Development, S.N.C. Biphenyl compounds which activate ppar-gamma type receptors and use thereof in cosmetic or pharmaceutical compositions
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
JP2007525406A (ja) 2003-12-04 2007-09-06 ワイス ビアリールスルホンアミドおよびその使用方法
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
EP1730118A1 (en) * 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
GB0403578D0 (en) 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP2083822A2 (en) * 2006-10-20 2009-08-05 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators

Also Published As

Publication number Publication date
NO20091957L (no) 2009-07-17
JP5047299B2 (ja) 2012-10-10
US20100022598A1 (en) 2010-01-28
RU2009118935A (ru) 2010-11-27
CN101528730A (zh) 2009-09-09
MX2009004112A (es) 2009-05-11
IL198004A0 (en) 2009-12-24
US8193228B2 (en) 2012-06-05
CA2666310C (en) 2012-07-31
CA2666310A1 (en) 2008-05-02
JP2010506919A (ja) 2010-03-04
WO2008051406A3 (en) 2008-07-24
AU2007309570B2 (en) 2012-07-12
EP2091937A2 (en) 2009-08-26
KR20090064458A (ko) 2009-06-18
WO2008051406A2 (en) 2008-05-02
AU2007309570A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
US8193228B2 (en) Substituted imidazole as bombesin receptor subtype-3 modulators
JP5319550B2 (ja) 置換スピロクロマノン誘導体
BRPI0709972A2 (pt) composto, composição farmacêutica, e, uso de um composto
EP2043634A2 (en) Substituted pyrazoles as ghrelin receptor antagonists
AU2007332867B2 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
WO2007041052A2 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007120688A2 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
US8183275B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
US8318767B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2006320797A1 (en) Heterocycle-substituted 3-alkyl azetidine derivatives

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]